This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Su, M.-w. Articles by Zhou, Y. Search for Related Content PubMed PubMed Citation Articles by Su, M.-w. Articles by Zhou, Y.

Aberrant Expression of T-Plastin in Sezary Cells¹

Chieng Genomics Centre, Laboratory of Predictive Medicine and Therapeutics, Vancouver Coastal Health Research Institute [M-w. S., I. D., Y. Z.]; Division of Dermatology, Department of Medicine, University of British Columbia [M-w. S., I. D., V. H., G. L., N. V., R. G., Y. Z.]; and British Columbia Cancer Agency [W. H. D., V. H., G. L., Y. Z.], Vancouver, British Columbia, V5Z 4E8 Canada

Mycosis fungoides (MF) and its leukemic variant, Sezary syndrome (SS), are the most common cutaneous T-cell lymphomas, with a combined incidence of 0.36 of 100,000 person-years. Although thought to be closely related to mature T-helper cells, the true nature of the cancer cells in MF/SS is unknown. In addition, there is no known specific marker for MF/SS cancer cells, which can result in difficulties in the diagnosis and treatment. To identify MF/SS-specific markers, Sezary cancer cells were analyzed with a global genomic screening tool, the modified representational difference analysis. It was discovered that unlike T-helper cells from healthy individuals or patients with nonmalignant dermatoses, Sezary cells from most patients with Sezary syndrome aberrantly expressed T-plastin mRNA and protein. This is the first time T-plastin protein, a cytoplasmic protein regulating actin assembly and cellular motility, has been detected in the hematopoietic cells. Therefore, T-plastin has the potential to be a Sezary cell-specific marker valuable for diagnostic and treatment of Sezary syndrome.

This article has been cited by other articles:

				A. Sors, F. Jean-Louis, E. Begue, L. Parmentier, L. Dubertret, M. Dreano, G. Courtois, H. Bachelez, and L. Michel Inhibition of I{kappa}B Kinase Subunit 2 in Cutaneous T-Cell Lymphoma Down-Regulates Nuclear Factor-{kappa}B Constitutive Activation, Induces Cell Death, and Potentiates the Apoptotic Response to Antineoplastic Chemotherapeutic Agents Clin. Cancer Res., February 1, 2008; 14(3): 901 - 911. [Abstract] [Full Text] [PDF]

				N. Ortonne, D. Huet, C. Gaudez, A. Marie-Cardine, V. Schiavon, M. Bagot, P. Musette, and A. Bensussan Significance of circulating T-cell clones in Sezary syndrome Blood, May 15, 2006; 107(10): 4030 - 4038. [Abstract] [Full Text] [PDF]

				M. Nebozhyn, A. Loboda, L. Kari, A. H. Rook, E. C. Vonderheid, S. Lessin, C. Berger, R. Edelson, C. Nichols, M. Yousef, et al. Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy Blood, April 15, 2006; 107(8): 3189 - 3196. [Abstract] [Full Text] [PDF]

				D. Huet, M. Bagot, D. Loyaux, J. Capdevielle, L. Conraux, P. Ferrara, A. Bensussan, and A. Marie-Cardine SC5 mAb Represents a Unique Tool for the Detection of Extracellular Vimentin as a Specific Marker of Sezary Cells J. Immunol., January 1, 2006; 176(1): 652 - 659. [Abstract] [Full Text] [PDF]

				M. Ralser, U. Nonhoff, M. Albrecht, T. Lengauer, E. E. Wanker, H. Lehrach, and S. Krobitsch Ataxin-2 and huntingtin interact with endophilin-A complexes to function in plastin-associated pathways Hum. Mol. Genet., October 1, 2005; 14(19): 2893 - 2909. [Abstract] [Full Text] [PDF]

				R. van Doorn, R. Dijkman, M. H. Vermeer, J. J. Out-Luiting, E. M. H. van der Raaij-Helmer, R. Willemze, and C. P. Tensen Aberrant Expression of the Tyrosine Kinase Receptor EphA4 and the Transcription Factor Twist in Sezary Syndrome Identified by Gene Expression Analysis Cancer Res., August 15, 2004; 64(16): 5578 - 5586. [Abstract] [Full Text] [PDF]